ESR1 and triple-negative breast carcinoma: Furthermore, stratified analysis showed that the miRNA signature was applicable to both triple-negative breast cancer (n=40) and other subtypes of breast cancers (ER+/PR+/Her2-, n=39; ER+/PR+/Her2+, n=5; ER-/PR-/Her2+, n=6) (Figure 6).